| Literature DB >> 30579356 |
Xuemei Han1, Zhaoshi Zheng1, Chunhui Wang2, Libo Wang3.
Abstract
BACKGROUND: Recent evidence suggests that long non-coding RNAs (lncRNAs) are key regulators in the pathological process of ischemic stroke (IS). Maternally expressed gene 3 (MEG3) was observed to be up-regulated in IS, acting as a competing endogenous RNA for miR-181b to regulate ischemic brain injury. The purpose of this study was to evaluate the association of tagSNPs in MEG3 (i.e., rs7158663 and rs4081134) and miR-181b rs322931 with IS risk.Entities:
Keywords: Ischemic stroke; Long non-coding RNAs; Maternally expressed gene 3; Polymorphism; miR-181
Mesh:
Substances:
Year: 2018 PMID: 30579356 PMCID: PMC6303848 DOI: 10.1186/s12944-018-0941-z
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Fig. 1SNPs related to lncRNA MEG3 and miR-181b. ▲ TagSNPs in MEG3 (i.e., rs7158663 and rs4081134). In silica analysis showed that the rs7158663 A can bind to transcriptional factors [C/EBPα, oct-1, and TATA bingding protein (TBP)] and the rs4081134 G can bind to transcriptional factors [(glucocorticoid receptor GR), C/EBPα, and c-Jun], whereas the rs7158663 G and rs4081134 A can not. ∆ Genome-wide association study indentified a functional polymorphism rs322931. The T allele exhibited higher levels of miR-181b
Characteristics of the study population
| Variables | Controls, | Patients with IS, | |
|---|---|---|---|
| Age, mean (± SD) | 58.6 (± 12.2) | 59.9 (± 10.9) | 0.06 |
| Gender (%) | |||
| Male | 414 (62.0) | 327 (64.2) | 0.43 |
| Female | 254 (38.0) | 182 (35.8) | |
| Hypertension, n (%) | |||
| Yes | 132 (19.8) | 280 (55.0) | < 0.001 |
| No | 536 (80.2) | 229 (45.0) | |
| Diabetes mellitus, n (%) | |||
| Yes | 72 (10.8) | 80 (15.7) | 0.01 |
| No | 596 (89.2) | 429 (84.3) | |
| TCH, mmol/L | 4.68 ± 0.79 | 5.04 ± 0.72 | < 0.001 |
| TG, mmol/L | 1.11 ± 0.36 | 1.84 ± 1.10 | < 0.001 |
| HDL-C, mmol/L | 1.56 ± 0.36 | 1.57 ± 0.38 | 0.53 |
| LDL-C, mmol/L | 2.26 ± 0.97 | 2.69 ± 0.98 | < 0.001 |
IS ischemic stroke, SD standard deviation; TCH, total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
Association between polymorphisms in MEG3/miR-181b and risk of ischemic stroke
| Polymorphism | Controls, | IS, | Crude OR (95% CI) | Adjusted OR(95% CI)† | Adjusted | |
|---|---|---|---|---|---|---|
| MEG3 rs7158663 | ||||||
| GG | 372 (55.7) | 252 (49.5) | 1.00 | 1.00 | ||
| AG | 242 (36.2) | 202 (39.7) | 1.23 (0.96–1.58) | 0.10 | 1.19 (0.92–1.55) | 0.19 |
| AA | 54 (8.1) | 55 (10.8) | 1.50 (1.00–2.26) | 0.05 | 1.49 (0.96–2.32) | 0.08 |
| Dominant model | 296 (44.3) | 257 (50.5) | 1.28 (1.02–1.62) | 0.04 | 1.25 (0.98–1.60) | 0.08 |
| Recessive model | 614 (91.9) | 454 (89.2) | 1.38 (0.93–2.04) | 0.11 | 1.39 (0.91–2.12) | 0.13 |
| MEG3 rs4081134 | ||||||
| GG | 392 (58.7) | 310 (60.9) | 1.00 | 1.00 | ||
| AG | 230 (34.4) | 167 (32.8) | 0.92 (0.72–1.18) | 0.50 | 0.87 (0.67–1.14) | 0.31 |
| AA | 46 (6.9) | 32 (6.3) | 0.88 (0.55–1.41) | 0.60 | 0.82 (0.49–1.37) | 0.44 |
| Dominant model | 276 (41.3) | 199 (39.1) | 0.91 (0.72–1.15) | 0.44 | 0.86 (0.67–1.11) | 0.25 |
| Recessive model | 622 (93.1) | 477 (93.7) | 0.91 (0.57–1.45) | 0.68 | 0.88 (0.53–1.45) | 0.61 |
| miR-181b rs322931 | ||||||
| CC | 473 (70.8) | 315 (61.9) | 1.00 | 1.00 | ||
| CT | 179 (26.8) | 170 (33.4) | 1.43 (1.11–1.84) | 0.006 | 1.48 (1.13–1.95) | 0.005 |
| TT | 16 (2.4) | 24 (4.7) | 2.25 (1.18–4.31) | 0.01 | 1.84 (0.91–3.70) | 0.09 |
| Dominant model | 195 (29.2) | 194 (38.1) | 1.49 (1.17–1.91) | 0.001 | 1.52 (1.17–1.97) | 0.002 |
| Recessive model | 652 (97.6) | 485 (95.3) | 2.02 (1.06–3.84) | 0.03 | 1.64 (0.82–3.27) | 0.16 |
IS ischemic stroke, OR odds ratio, CI confidence interval. †Adjusted by age, gender, hypertension, and diabetes mellitus
Stratification analyses of polymorphisms in MEG3/miR-181b and clinical features of IS
| Genotypes | TCH (mmol/L) | TG (mmol/L) | HDL-C (mmol/L) | LDL-C (mmol/L) | ||||
|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |||||
| MEG3 rs7158663 | ||||||||
| GG | 5.07 ± 0.72 | 1.82 ± 1.08 | 1.56 ± 0.38 | 2.74 ± 0.98 | ||||
| AG/AA | 5.02 ± 0.72 | 0.36 | 1.87 ± 1.12 | 0.63 | 1.58 ± 0.39 | 0.54 | 2.63 ± 0.97 | 0.18 |
| MEG3 rs4081134 | ||||||||
| GG | 5.07 ± 0.66 | 1.84 ± 1.06 | 1.58 ± 0.39 | 2.71 ± 0.93 | ||||
| AG/AA | 5.00 ± 0.80 | 0.31 | 1.86 ± 1.16 | 0.81 | 1.55 ± 0.37 | 0.36 | 2.65 ± 1.05 | 0.49 |
| miR-181b rs322931 | ||||||||
| CC | 5.01 ± 0.71 | 1.85 ± 1.09 | 1.58 ± 0.37 | 2.60 ± 0.96 | ||||
| CT/TT | 5.10 ± 0.72 | 0.17 | 1.84 ± 1.12 | 0. 92 | 1.56 ± 0.40 | 0.73 | 2.82 ± 1.00 | 0.01 |
IS ischemic stroke, TCH total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SD standard deviation
The ancestral allele frequencies of the 3 SNPs based on data from the 1000 Genomes Project
| Population | rs7158663 G, % | rs4081134 G, % | rs322931 C, % |
|---|---|---|---|
| HapMap-CEU | 50.9 | 62.6 | 81.7 |
| HapMap-HCB | 74.4 | 77.9 | 84.9 |
| HapMap-JPT | 66.9 | 80.8 | 83.1 |
| HapMap-YRI | 12.8 | 77.9 | 84.8 |
| HAPMAP-ASW | 23.5 | 80.6 | 81.6 |
| HAPMAP-CHB | 74.4 | 78.1 | 84.2 |
| HAPMAP-CHD | 81.8 | 72.4 | 84.9 |
| HAPMAP-GIH | 69.9 | 63.6 | 79.0 |
| HAPMAP-LWK | 25.0 | 80.6 | 80.9 |
| HAPMAP-MEX | 59.0 | 74.0 | 65.3 |
| HAPMAP-MKK | 32.5 | 79.0 | 80.7 |
| HAPMAP-TSI | 52.8 | 65.3 | 88.1 |
| Data in the current study | 73.8 | 75.9 | 84.2 |
CEU, Utah residents with Northern and Western European ancestry from the CEPH collection, HCB Han Chinese in Beijing, China, JPT Japanese in Tokyo, Japan, YRI Yoruba in Ibadan, Nigeria, ASW African ancestry in Southwest USA, CHB Han Chinese in Beijing, China, CHD Chinese in Metropolitan Denver, Colorado, GIH Gujarati Indians in Houston, Texas, LWK Luhya in Webuye, Kenya, MEX Mexican ancestry in Los Angeles, California, MKK Maasai in Kinyawa, Kenya, TSI Toscans in Italy
Combined analyses of polymorphisms in MEG3/miR-181b with IS risk
| Combined genotypes | Controls, | IS, | OR (95% CI) | |
|---|---|---|---|---|
| MEG3 rs7158663- miR-181b rs322931 | ||||
| rs7158663 GG + rs322931 CC | 267 (40.0) | 154 (30.3) | 1.00 | |
| rs7158663 GG + rs322931 CT/TT | 105 (15.7) | 98 (19.3) | 1.62 (1.15–2.27) | 0.005 |
| rs7158663 AG/AA + rs322931 CC | 206 (30.8) | 161 (31.6) | 1.36 (1.02–1.80) | 0.04 |
| rs7158663 AG/AA + rs322931 CT/TT | 90 (13.5) | 96 (18.9) | 1.85 (1.30–2.62) | 0.001 |
| MEG3 rs4081134- miR-181b rs322931 | ||||
| rs4081134 GG + rs322931 CC | 281 (42.1) | 203 (39.9) | 1.00 | |
| rs4081134 GG + rs322931 CT/TT | 111 (16.6) | 107 (21.0) | 1.33 (0.97–1.84) | 0.08 |
| rs4081134 AG/AA + rs322931 CC | 192 (28.7) | 112 (22.0) | 0.81 (0.60–1.08) | 0.16 |
| rs4081134 AG/AA + rs322931 CT/TT | 84 (12.6) | 87 (17.1) | 1.43 (1.01–2.03) | 0.04 |
IS ischemic stroke, OR Odds ratio, CI confidence interval
Haplotype analysis of the MEG3/miR-181b polymorphisms between cases and controls
| Haplotypea | Controls, N (%) | IS, N (%) | OR (95% CI) | |
|---|---|---|---|---|
| GGC | 653 (48.9) | 429 (42.1) | 1.00 | |
| AGC | 206 (15.4) | 204 (20.0) | 1.51 (1.20–1.90) | < 0.001 |
| GAC | 180 (13.5) | 127 (12.5) | 1.07 (0.83–1.39) | 0.59 |
| GGT | 111 (8.3) | 113 (11.1) | 1.55 (1.16–2.07) | 0.003 |
| AAC | 85 (6.4) | 40 (3.9) | 0.72 (0.48–1.06) | 0.10 |
| AGT | 44 (3.3) | 41 (4.0) | 1.42 (0.91–2.21) | 0.12 |
| GAT | 41 (3.1) | 37 (3.6) | 1.37 (0.87–2.18) | 0.18 |
aOnly the frequency > 3% was presented
Logistic regression analysis for independent risk factors of ischemic stroke
| Variables | B | Walds | OR (95% CI) | |
|---|---|---|---|---|
| Hypertension | 1.60 | 107.13 | 4.97 (3.67–6.73) | < 0.001 |
| TCH | 0.21 | 4.70 | 1.24 (1.02–1.49) | 0.03 |
| TG | 1.77 | 148.89 | 5.89 (4.43–7.83) | < 0.001 |
| LDL-C | 0.64 | 59.63 | 1.90 (1.61–2.24) | < 0.001 |
| rs322931 CT/TT | 0.34 | 4.82 | 1.41 (1.04–1.91) | 0.03 |
OR odds ratio, CI confidence interval, TCH total cholesterol, TG triglyceride, LDL-C low-density lipoprotein cholesterol
Fig. 2Effect of the rs322931 on transcriptional activity. The fragment containing the rs322931 C or rs322931 T allele was transfected into HEK293 cells. pGL3-SV40 was used as an internal control and relative luciferase activity was measured 48 h post-transfection. Data are expressed as mean ± standard error (** P < 0.01)